New personalized melanoma vaccine lowers death risk by 42 percent

A personalized mRNA vaccine designed to treat melanoma reduced the risk of death or cancer recurrence by 42 percent compared to standard care, according to results announced Thursday by Merck and Moderna. This finding marks a substantial milestone in the fight against the deadliest form of skin cancer and signals a potential shift in how oncologists approach treatment.

The data comes from a late-stage clinical trial that involved 1,137 patients diagnosed with stage IIB through IV melanoma. All participants had previously undergone surgery to remove their tumors before entering the study. The trial was structured as a randomized experiment where two-thirds of the patients received the personalized mRNA vaccine in combination with standard therapy, while the remaining one-third received only the standard treatment.

The standard care used in the study was Keytruda, an established monoclonal antibody drug manufactured by Merck. The results suggest that adding the customized vaccine to this existing regimen offers a clear benefit over using the antibody alone. Because the vaccine is tailored to the specific mutations found in each patient's tumor, the findings support the growing idea that individualized medicines can create a new paradigm for cancer therapy.

Merck and Moderna initially shared the positive outcome in August but withheld specific details until the data could be presented at a major scientific gathering. The full dataset was scheduled to be shown at the European Society of Medical Oncology conference, which is currently taking place in Madrid, Spain. However, the companies released the top-line figures early after an oncology news outlet reported on the results ahead of the planned Saturday presentation, breaking the traditional embargo.

Stéphane Bancel, the chief executive officer of Moderna, emphasized the company's long-standing belief in the technology. He stated in a written declaration that the team has always believed mRNA technology could enable cancer treatments matched uniquely to each patient's tumor. He described the trial results as a defining moment for that vision, noting that it shows what is possible when the industry rethinks how medicines are developed.

Bancel added that the outcome reinforces the conviction that mRNA has the potential to fundamentally change cancer treatment. The full data from the trial has already been accepted for publication in the New England Journal of Medicine. Regulatory authorities are now being engaged by both pharmaceutical partners to move the vaccine toward formal approval for use.

For patients and healthcare providers in California and beyond, these results provide concrete evidence that personalized vaccines can significantly improve survival metrics in advanced melanoma cases. The early release of the data highlights the intense scrutiny and anticipation surrounding new oncology therapies in the current market.